Companion Spine

Companion Spine announced today that it added $5 million to close its Series A financing round at $60.1 million.

The initial $55 million came in through fundraising announced in February 2022.

The French-American spine pain-management surgery company aims to address two large indications in the market. It seeks to treat lumbar spinal stenosis (LSS) and degenerative disc disease (DDD) without requiring spine fusion surgery.

Based in Bordeaux, France, and New York, Companion Spine focuses on interventional spine pain treatment. It develops revisable, minimally invasive implants centered around motion preservation. The company also offers precision diagnostics for comprehensive spine health throughout the care continuum.

Companion Spine said in a news release that its funding allows the introduction of its DIAM and LISA products. DIAM, the company’s flagship product, treats DDD. The company obtained LISA through its acquisition of French compan…

Diagnostic and interventional spine surgery company Companion Spine announced today that it raised $55 million in a Series A financing.

Companion Spine, which has headquarters in New York and Bordeaux, France, had its financing led by Viscogliosi Brothers, the company’s co-founder and historical shareholder, and jointly invested by a leading global medtech company.

Viscogliosi Brothers formed Companion Spine to focus on spine pain treatment, motion preservation, precision diagnostics and interventional care, according to a news release. Funds raised in the Series A round will be used primarily for the development and commercialization of the company’s minimally invasive diagnostic and therapeutic solutions for treating degenerative disc disease (DDD) and lumbar spine stenosis (LSS).

Companion Spine’s portfolio, which come sin part from a 2020 acquisition of regulatory and clinical property from Medtronic, includes six patent families co…